CLINICAL TRIALS PROFILE FOR OXCARBAZEPINE

All Clinical Trials for OXCARBAZEPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00050934 ↗	Pediatric Epilepsy Study	Completed	Novartis Pharmaceuticals	Phase 3	2002-06-01	This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00050947 ↗	Pediatric Epilepsy Study	Completed	Novartis Pharmaceuticals	Phase 3	2002-07-01	This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
NCT00068770 ↗	Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT	Terminated	National Cancer Institute (NCI)	Phase 2	2003-10-01	RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 ↗	Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT	Terminated	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2003-10-01	RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 ↗	Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT	Terminated	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2003-10-01	RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.

Clinical Trial Conditions for OXCARBAZEPINE

Condition Name

Condition Name for OXCARBAZEPINE
Intervention	Trials
Epilepsy	13
Seizures	5
Healthy	5
Bipolar Disorder	4

Condition MeSH

Condition MeSH for OXCARBAZEPINE
Intervention	Trials
Epilepsy	21
Seizures	13
Epilepsies, Partial	11
Neuralgia	6

Clinical Trial Locations for OXCARBAZEPINE

Trials by Country

Trials by Country for OXCARBAZEPINE
Location	Trials
United States	139
Japan	34
Mexico	17
Germany	11
Canada	10

Trials by US State

Trials by US State for OXCARBAZEPINE
Location	Trials
Texas	8
New York	8
Georgia	8
Pennsylvania	7
Florida	7

Clinical Trial Progress for OXCARBAZEPINE

Clinical Trial Phase

Clinical Trial Phase for OXCARBAZEPINE
Clinical Trial Phase	Trials
Phase 4	23
Phase 3	10
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for OXCARBAZEPINE
Clinical Trial Phase	Trials
Completed	46
Terminated	5
Not yet recruiting	3

Clinical Trial Sponsors for OXCARBAZEPINE

Sponsor Name

Sponsor Name for OXCARBAZEPINE
Sponsor	Trials
Novartis	5
Novartis Pharmaceuticals	5
Roxane Laboratories	5

Sponsor Type

Sponsor Type for OXCARBAZEPINE
Sponsor	Trials
Other	61
Industry	38
NIH	2